Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech stocks hitting 52-week highs on March 25)
- Axsome Therapeutics Inc (NASDAQ: AXSM)
- Catalyst Pharmaceuticals Inc (NASDAQ: CPRX)
- CYCLERION THERA/SH (NASDAQ: CYCNV)
- Veracyte Inc (NASDAQ: VCYT)
Down In The Dumps
(Biotech stocks hitting 52-week lows on March 25)
- Adamas Pharmaceuticals Inc (NASDAQ: ADMS)
- Assembly Biosciences Inc (NASDAQ: ASMB)
- Avadel Pharmaceuticals PLC (NASDAQ: AVDL)
- Evogene Ltd (NASDAQ: EVGN)
- Harpoon Therapeutics Inc (NASDAQ: HARP)
- Proteostasis Therapeutics Inc (NASDAQ: PTI)(reported disappointing Phase 1 results for its cystic fibrosis triplet therapy PTI-801, PTI-808 and PTI-428 and separate studies of PTI-801 and PTI 428 as add-on therapies to tezacaftor/ivacaftor)
- Unity Biotechnology Inc (NASDAQ: UBX)
- Zafgen Inc (NASDAQ: ZFGN)
Stock In Focus AbbVie's Psoriasis Drug Approved In Japan
AbbVie Inc (NYSE: ABBV) announced Japanese approval of its Skyrizi, an interleukin-23 inhibitor for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis, in adult patients who have an inadequate response to conventional therapies.
"This approval marks the first country approval in the world for SKYRIZI," AbbVie said.
PhaseBio Finalizes A New Term Loan Agreement
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS), which went public in late 2018, said it has secured up to $15 million in funds to support the clinical advancement of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, as well as for repaying its existing term loans in full.
The stock rallied 4.38 percent to $7.15 in after-hours trading.
Veracyte Presents New Findings Using Genomic Diagnostic Tool
Veracyte said it has presented new data from genomic diagnostic tool Affirma Xpression Atlas that suggested the majority of newly diagnosed medullary thyroid cancers, or MTC, are associated with variants from three genes. The findings were presented at the ENDO 2019, the Endocrine Society's annual meeting.
The stock rose 1.44 percent to $26.13 in after-hours trading.
See Also: More Pain For Recro Pharma: FDA Rejects Meloxicam NDA For Second Time
Celgene Makes Regulatory Filing For Multiple Myeloma Drug
Celgene Corporation (NASDAQ: CELG) submitted a NDA to the FDA for its ozanimod for the treatment of adults with relapsing forms of multiple sclerosis. The submission was based on efficacy and safety data from the SUNBEAM and RADIANCE Part B Phase 3 trials.
""With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in 2020," Celgene said.
CorMedix To Begin Trading On Reverse Stock Split-adjusted Basis
CorMedix Inc. (NYSE: CRMD) said its previously announced 1-for-5 reverse stock split of its common stock will take effect 9 a.m. ET Tuesday.
The stock gained 1.2 percent to $1.68 in after-hours trading.
CytomX CFO Departs
CytomX Therapeutics Inc (NASDAQ: CTMX) announced the resignation of CFO Debanjan Ray, who is leaving to take up the position of CEO at a newly-formed private biotech company. CytomX said it is initiating a search for filling the role of CFO.
The stock slipped 1.64 percent to $10.5735 in after-hours trading.
Novartis' Sandoz Unit Announces Exclusive U.S. Launch of Generic Lung Blood Pressure Drug
Novartis AG (NYSE: NVS)'s Sandoz unit announced the U.S. availability of Treprostinil injection, which is indicated for treating pulmonary arterial hypertension. The product is the first fully substitutable AP-rated generic version of Remodulin, sold by United Therapeutics Corporation (NASDAQ: UTHR). Sandoz also said it has 180 days of marketing exclusivity for the product.
Myokardia Inc (NASDAQ: MYOK) announced it has commenced an underwritten public offering to sell $200 million shares of its common stock. All shares are to be sold by the company.
The company said it intends to use the net proceeds from the offering, along with its existing cash, cash equivalents and short-term and long-term investments, to support its pipeline development programs.
The stock slipped 3.59 percent to $50.01 in after-hours trading.
Zomedica Pharmaceuticals Corp (NYSE: ZOM) priced its previously-announced underwritten public offering of 6.521 million common shares, at a price 46 cents per share. The company said it expects to receive gross proceeds of approximately $3 million from the offering. The offering is expected to close on or about March 28.
The shares fell 5.30 percent to 54 cents in after-hours trading.
On The Radar Earnings
See more from Benzinga
- The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
- The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback
- The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.